Rasha Al-Lamee(@rallamee) 's Twitter Profileg
Rasha Al-Lamee

@rallamee

Interventional Cardiology Consultant, Clinical Trialist, Imperial College London. Wife to a rugby obsessed husband and mum to a football obsessed son

ID:916585888574042113

calendar_today07-10-2017 08:47:59

1,5K Tweets

5,5K Followers

541 Following

Dr Thomas Keeble(@DrKeeble) 's Twitter Profile Photo

I am doing 85 mile Etape Caledonia in 2 weeks raising money for @essex_cf SENZO supporting adults with learning disability in Essex. Raising £5k to refit a shop for adult vocational training. Medlife Crisis (Rohin) Rasha Al-Lamee Tony Young Justin Edinburgh 3 Foundation CellAED
essexcommunityfoundation.enthuse.com/cf/senzo-chari…

account_circle
Davide Capodanno(@DFCapodanno) 's Twitter Profile Photo

2024 is fast approaching and to prepare for the Course, this year we have prepared the , which will put your knowledge of the journal and cardiovascular medicine to the test.

It will unfold in 2 parts: an online challenge on social media (Level 1) and then

#EuroPCR 2024 is fast approaching and to prepare for the Course, this year we have prepared the #EIJchallenge, which will put your knowledge of the journal and cardiovascular medicine to the test. It will unfold in 2 parts: an online challenge on social media (Level 1) and then
account_circle
Rasha Al-Lamee(@rallamee) 's Twitter Profile Photo

No rest for the ORBITA team! Recruitment is going strong for ORBITA-FIRE which is being led by Fiyyaz Ahmed-Jushuf. Thank you to Klio Konstantinou and the Essex CTC a fantastic case this week
@Drkeeble
@dizzledavies73

No rest for the ORBITA team! Recruitment is going strong for ORBITA-FIRE which is being led by @fiyyazAJ. Thank you to @kliokon and the Essex CTC a fantastic case this week @Drkeeble @dizzledavies73
account_circle
Christopher Rajkumar(@rajkumar_chris) 's Twitter Profile Photo

Q: Does blinding matter in RCTs of surgical procedures? A: Depends on the endpoint JAMA Surgery

We compared placebo-controlled and open-label surgical trials to identify when the placebo effect is most powerful Rasha Al-Lamee Katie Thomas NHLI

jamanetwork.com/journals/jamas…

Q: Does blinding matter in RCTs of surgical procedures? A: Depends on the endpoint @JAMASurgery We compared placebo-controlled and open-label surgical trials to identify when the placebo effect is most powerful @rallamee @KatieEljadi @ImperialNHLI jamanetwork.com/journals/jamas…
account_circle
Rasha Al-Lamee(@rallamee) 's Twitter Profile Photo

It was a pleasure to visit the Arterius team today and hear all about their ongoing projects in cardiovascular and peripheral vascular disease

It was a pleasure to visit the Arterius team today and hear all about their ongoing projects in cardiovascular and peripheral vascular disease
account_circle
Shockwave Medical(@ShockwaveIVL) 's Twitter Profile Photo

Hear from Drs Rasha Al-Lamee & Michael Foley who discuss the ORBITA-COSMIC trial results presented at .

The ORBITA-COSMIC trial results show that the reduced angina frequency and improved heart disease related quality of life. And while the imaging endpoint

account_circle
NIHR Imperial BRC(@ImperialBRC) 's Twitter Profile Photo

Congratulations to Rasha Al-Lamee and the rest of the team for the latest update from the ORBITA-COSMIC. Another great output for the NIHR Imperial BRC Cardiovascular Theme Imperial NHS 💙 Imperial College London

account_circle
American College of Cardiology(@ACCinTouch) 's Twitter Profile Photo

In a new edition of ACC's Cardiology Hour, EiC Dr. Valentin Fuster is joined by expert panelists in a lively discussion on the top LBCTs released during , such as RELIEVE-HF, EMPACT-MI, and more!

Watch the full video here: bit.ly/43SAiTv

In a new edition of ACC's Cardiology Hour, #JACC EiC Dr. Valentin Fuster is joined by expert panelists in a lively discussion on the top LBCTs released during #ACC24, such as RELIEVE-HF, EMPACT-MI, and more! Watch the full video here: bit.ly/43SAiTv
account_circle
Imperial NHS 💙(@ImperialNHS) 's Twitter Profile Photo

.Rasha Al-Lamee, interventional cardiology consultant Imperial NHS 💙, said: 'Our study wasn’t able to show how this device works, but it does seem to reduce angina frequency in patients with refractory angina.

'Giving these patients another option for treatment is a positive step.”

account_circle
Imperial NHS 💙(@ImperialNHS) 's Twitter Profile Photo

Well done to Dr Rasha Al-Lamee, interventional cardiologist Imperial NHS 💙 and senior author of the ORBITA-COSMIC study, and the wider research team on these positive findings 👏🏽

NHLI @Rallamee Ramzi Khamis

account_circle
Ritu Thamman MD(@iamritu) 's Twitter Profile Photo

-COSMIC Rasha Al-Lamee John Foley presents at

In refractory angina patients an CS occluder device shows improved subendocardial perfusion by stress (not transmural) and reduces
angina frequency & improved QOL 🆚 placebo bit.ly/3TSC3vo

#ORBITA-COSMIC @rallamee John Foley presents at #ACC24 In refractory angina patients an CS occluder device shows improved subendocardial perfusion by stress #WhyCMR (not transmural) and reduces angina frequency & improved QOL 🆚 placebo bit.ly/3TSC3vo
account_circle
Mayooran Shan(@MayooranShan) 's Twitter Profile Photo

Coronary sinus reducer reduces symptom burden in patients with refractory angina unsuitable for revascularisation. It appears
to improve endocardial blood flow at stress on .

Brilliant study by Rasha Al-Lamee Michael Foley Matthew Shun-Shin et al
NHLI The Lancet

Coronary sinus reducer reduces symptom burden in patients with refractory angina unsuitable for revascularisation. It appears to improve endocardial blood flow at stress on #whyCMR. Brilliant study by @rallamee @MikeFoley89 @mshunshin et al @ImperialNHLI #ACC2024 @TheLancet
account_circle